Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling

• Published in: Biomolecules (Basel, Switzerland) Vol. 13; no. 8; p. 1255
• Main Authors: Grolleau, Emmanuel, Candiracci, Julie, Lescuyer, Gaelle, Barthelemy, David, Benzerdjeb, Nazim, Haon, Christine, Geiguer, Florence, Raffin, Margaux, Hardat, Nathalie, Balandier, Julie, Rabeuf, Rémi, Chalabreysse, Lara, Wozny, Anne-Sophie, Rommelaere, Guillaume, Rodriguez-Lafrasse, Claire, Subtil, Fabien, Couraud, Sébastien, Herzog, Marielle, Payen-Gay, Lea
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.08.2023; MDPI
• Subjects: Antibodies; Antigens; Applications; Automation; Biomarkers; Blood plasma; Brain cancer; Cancer therapies; ctDNA; Diagnosis; DNA; DNA fingerprinting; DNA methylation; Epigenetics; Genetic aspects; H3K27Me3 nucleosome; Health aspects; histone PTM; Immunoassay; Kinases; liquid biopsy; Lung cancer; Methodology; Non-small cell lung carcinoma; NSCLC; Nucleosomes; Patients; Plasma; Statistics; Tumorigenesis; Tumors; France; United States > US; H3K27Me3 nucleosome; NSCLC; biomarkers; histone PTM; epigenetics; ctDNA; liquid biopsy; MRD
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom13081255

The molecular profiling of circulating tumor DNA (ctDNA) is a helpful tool not only in cancer treatment, but also in the early detection of relapse. However, the clinical interpretation of a ctDNA negative result remains challenging. The characterization of circulating nucleosomes (carrying cell-free DNA) and associated epigenetic modifications (playing a key role in the tumorigenesis of different cancers) may provide useful information for patient management, by supporting the contributive value of ctDNA molecular profiling. Significantly elevated concentrations of H3K27Me3 nucleosomes were found in plasmas at the diagnosis, and during the follow-up, of NSCLC patients, compared to healthy donors (p-value < 0.0001). By combining the H3K27Me3 level and the ctDNA molecular profile, we found that 25.5% of the patients had H3K27Me3 levels above the cut off, and no somatic alteration was detected at diagnosis. This strongly supports the presence of non-mutated ctDNA in the corresponding plasma. During the patient follow-up, a high H3K27Me3-nucleosome level was found in 15.1% of the sample, despite no somatic mutations being detected, allowing the identification of disease progression from 43.1% to 58.2% over molecular profiling alone. Measuring H3K27Me3-nucleosome levels in combination with ctDNA molecular profiling may improve confidence in the negative molecular result for cfDNA in lung cancer at diagnosis, and may also be a promising biomarker for molecular residual disease (MRD) monitoring, during and/or after treatment.